Maria Dall'Era, MD
Professor
Medicine
School of Medicine

Dr. Dall'Era received her undergraduate degree in Immunology from the University of California, Berkeley and completed her medical degree, residency in internal medicine, chief residency, and rheumatology fellowship at the University of California, San Francisco. She is a clinical researcher and practicing rheumatologist, specializing in systemic lupus erythematosus (SLE).

Dr. Dall'Era's scholarly activities focus on the development of novel therapies and the epidemiology and outcomes of people living with SLE and lupus nephritis. She is the PI of a CDC-funded population- based longitudinal lupus cohort in the San Francisco Bay Area called the California Lupus Epidemiology Study and the PI on clinical trials focused on SLE and lupus nephritis (LN).

She holds several international and national leadership positions including serving as Co-Chair of the Lupus Therapeutics Board of Directors, Co-Chair of the LRA's Lupus Industry Council, and member of the Lupus Accelerating Breakthroughs Consortium Research Committee. She is also a steering committee member of the Lupus Academy and Lupus Forum. She serves as a member of the core leadership team overseeing the development of the American College of Rheumatology's Guidelines for the Treatment of SLE and LN.

She has authored numerous publications in the areas of SLE and lupus nephritis. She is a co-author of the Treatment of Lupus Nephritis chapters in Up-To-Date.

She has received several honors and awards for her work including the UCSF Exceptional Physician Award, the Ephraim Engleman Award for Arthritis Research, the Edmund L. Dubois Memorial Lectureship Award from the American College of Rheumatology, and the Evelyn V. Hess award from the Lupus Foundation of America.

• Physical inactivity exacerbates pathologic inflammatory signalling at the single cell level in patients with systemic lupus.
  EBioMedicine 2024 Patterson SL, Van Phan H, Ye CJ, Lanata C, González SC, Park J, Criswell LA, Barbour KE, Yazdany J, Dall'Era M, Sirota M, Katz P, Langelier CR
• Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and ALMS.
  Lupus science & medicine 2024 Dall'Era M, Kalunian K, Solomons N, Truman M, Hodge LS, Yap E, Askanase AD
• Cell-Specific Transposable Element and Gene Expression Analysis Across Systemic Lupus Erythematosus Phenotypes.
  ACR open rheumatology 2024 Cutts Z, Patterson S, Maliskova L, Taylor KE, Ye CJ, Dall'Era M, Yazdany J, Criswell LA, Fragiadakis GK, Langelier C, Capra JA, Sirota M, Lanata CM
• Impact of Glucocorticoid Dose on Complete Response, Serious Infections, and Mortality During the Initial Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis of the Control Arms of Randomized Controlled Trials.
  Arthritis & rheumatology (Hoboken, N.J.) 2024 Figueroa-Parra G, Cuéllar-Gutiérrez MC, González-Treviño M, Sanchez-Rodriguez A, Flores-Gouyonnet J, Meade-Aguilar JA, Prokop LJ, Murad MH, Dall'Era M, Rovin BH, Houssiau F, Tamirou F, Fervenza FC, …
• Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations.
  Lupus science & medicine 2024 Askanase AD, Furie RA, Dall'Era M, Bomback AS, Schwarting A, Zhao MH, Bruce IN, Khamashta M, Rubin B, Carroll A, Daniels M, Levy RA, van Vollenhoven R, Urowitz MB
• Positive psychosocial factors may protect against perceived stress in people with systemic lupus erythematosus with and without trauma history.
  Lupus science & medicine 2024 DeQuattro K, Trupin L, Patterson S, Rush S, Gordon C, Greenlund KJ, Barbour KE, Lanata C, Criswell LA, Dall'Era M, Yazdany J, Katz PP
• Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis.
  bioRxiv : the preprint server for biology 2024 Horisberger A, Griffith A, Keegan J, Arazi A, Pulford J, Murzin E, Howard K, Hancock B, Fava A, Sasaki T, Ghosh T, Inamo J, Beuschel R, Cao Y, Preisinger K, Gutierrez-Arcelus M, Eisenhaure TM, …
• Screening of Environmental Chemicals to Characterize Exposures in Participants With Systemic Lupus Erythematosus.
  Arthritis & rheumatology (Hoboken, N.J.) 2024 Lanata CM, Taylor KE, Hurst-Hopf J, Nititham J, Blazer A, Trupin L, Katz P, Dall'Era M, Yazdany J, Chung SA, Abrahamsson D, Gerona R, Criswell LA
• Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the Accelerating Medicines Partnership Lupus Network.
  Arthritis research & therapy 2024 Izmirly PM, Kim MY, Carlucci PM, Preisinger K, Cohen BZ, Deonaraine K, Zaminski D, Dall'Era M, Kalunian K, Fava A, Belmont HM, Wu M, Putterman C, Anolik J, Barnas JL, Diamond B, Davidson A, Wofsy D, …
• Prevalence of clinically meaningful antiphospholipid antibodies in patients with systemic lupus erythematosus varies by race and ethnicity.
  Annals of the rheumatic diseases 2024 Yelnik CM, Xie X, Guerra MM, Costedoat-Chalumeau N, Khosroshahi A, Kamen DL, Schwartz N, Katz P, Minett M, Amoss RT, Fu A, Guettrot-Imbert G, Lazaro E, Le Guern V, Oates J, Dall'Era M, Yazdany J, …
• Local Ancestry at the Major Histocompatibility Complex Region is Not a Major Contributor to Disease Heterogeneity in a Multiethnic Lupus Cohort.
  Arthritis & rheumatology (Hoboken, N.J.) 2024 Solomon O, Lanata CM, Adams C, Nititham J, Taylor KE, Chung SA, Yazdany J, Dall'Era M, Pons-Estel BA, Tusié-Luna T, Tsao B, Morand E, Alarcón-Riquelme ME, Barcellos LF, Criswell LA
• Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial.
  The Lancet. Rheumatology 2024 Chakravarty EF, Utset T, Kamen DL, Contreras G, McCune WJ, Aranow C, Kalunian K, Massarotti E, Clowse MEB, Rovin BH, Lim SS, Majithia V, Dall'Era M, Looney RJ, Erkan D, Saxena A, Olsen NJ, Ko K, …
• Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis.
  JCI insight 2024 Fava A, Buyon J, Magder L, Hodgin J, Rosenberg A, Demeke DS, Rao DA, Arazi A, Celia AI, Putterman C, Anolik JH, Barnas J, Dall'Era M, Wofsy D, Furie R, Kamen D, Kalunian K, James JA, Guthridge J, Atta…
• Economic insecurities and patient-reported outcomes in patients with systemic lupus erythematosus in the USA: a cross-sectional analysis of data from the California Lupus Epidemiology Study.
  The Lancet. Rheumatology 2023 Sandoval-Heglund D, Roberts E, Park J, Dall'Era M, Lanata C, Barbour KE, Greenlund KJ, Gordon C, Katz PP, Yazdany J
• Cell-Specific Transposable Element Gene Expression Analysis Identifies Associations with Systemic Lupus Erythematosus Phenotypes.
  bioRxiv : the preprint server for biology 2023 Cutts Z, Patterson S, Maliskova L, Taylor KE, Ye C, Dall'Era M, Yazdany J, Criswell L, Fragiadakis GK, Langelier C, Capra JA, Sirota M, Lanata CM
• Differential regulation of the interferon response in systemic lupus erythematosus distinguishes patients of Asian ancestry.
  RMD open 2023 Rector I, Owen KA, Bachali P, Hubbard E, Yazdany J, Dall'era M, Grammer AC, Lipsky PE
• The association of trauma with self-reported flares and disease activity in systemic lupus erythematosus (SLE).
  Rheumatology (Oxford, England) 2023 Katz P, Patterson SL, DeQuattro K, Lanata CM, Barbour KE, Greenlund KJ, Gordon C, Criswell LA, Dall'Era M, Yazdany J
• Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE.
  Lupus science & medicine 2023 Askanase AD, Aranow C, Kim MY, Kamen DL, Arriens C, Khalili L, Tang W, Barasch J, Dall'Era M, Mackay M
• Medication Cost Concerns and Disparities in Patient-Reported Outcomes Among a Multiethnic Cohort of Patients With Systemic Lupus Erythematosus.
  The Journal of rheumatology 2023 Aguirre A, DeQuattro K, Shiboski S, Katz P, Greenlund KJ, Barbour KE, Gordon C, Lanata C, Criswell LA, Dall'Era M, Yazdany J
• Non-Full House Membranous Lupus Nephritis Represents a Clinically Distinct Subset.
  Kidney360 2023 Ye J, Croom N, Troxell ML, Kambham N, Zuckerman JE, Andeen N, Dall'Era M, Hsu R, Walavalkar V, Laszik ZG, Urisman A
• The use of combination monoclonal antibody therapies in lupus-where are we now?
  Rheumatology (Oxford, England) 2023 Rua J, Dall'Era M, Isenberg D
• Molecular pathways identified from single nucleotide polymorphisms demonstrate mechanistic differences in systemic lupus erythematosus patients of Asian and European ancestry.
  Scientific reports 2023 Owen KA, Bell KA, Price A, Bachali P, Ainsworth H, Marion MC, Howard TD, Langefeld CD, Shen N, Yazdany J, Dall'era M, Grammer AC, Lipsky PE
• Perceived Stress and Prediction of Worse Disease Activity and Symptoms in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort.
  Arthritis care & research 2023 Patterson S, Trupin L, Hartogensis W, DeQuattro K, Lanata C, Gordon C, Barbour KE, Greenlund KJ, Dall'Era M, Yazdany J, Katz P
• Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial.
  ACR open rheumatology 2022 Wallace DJ, Dörner T, Pisetsky DS, Sanchez-Guerrero J, Patel AC, Parsons-Rich D, Le Bolay C, Drouin EE, Kao AH, Guehring H, Dall'Era M
• High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership.
  Rheumatology (Oxford, England) 2022 Carlucci PM, Li J, Fava A, Deonaraine KK, Wofsy D, James JA, Putterman C, Diamond B, Davidson A, Fine DM, Monroy-Trujillo J, Atta MG, DeJager W, Guthridge JM, Haag K, Rao DA, Brenner MB, Lederer JA, …
• Real-world treatment utilization and economic implications of lupus nephritis disease activity in the United States.
  Journal of managed care & specialty pharmacy 2022 Dall'Era M, Kalunian K, Eaddy M, Ogbonnaya A, Farrelly E, Turowski E, Birardi V, Solomons N, Randhawa S, Mina-Osorio P
• Causes of Death Among Individuals With Systemic Lupus Erythematosus by Race and Ethnicity: A Population-Based Study.
  Arthritis care & research 2022 Taylor T, Anastasiou C, Ja C, Rush S, Trupin L, Dall'Era M, Katz P, Barbour KE, Greenlund KJ, Yazdany J, Gianfrancesco MA
• Dynamics of Methylation of CpG Sites Associated With Systemic Lupus Erythematosus Subtypes in a Longitudinal Cohort.
  Arthritis & rheumatology (Hoboken, N.J.) 2022 Lanata CM, Nititham J, Taylor KE, Solomon O, Chung SA, Blazer A, Trupin L, Katz P, Dall'Era M, Yazdany J, Sirota M, Barcellos LF, Criswell LA
• Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment.
  Frontiers in immunology 2022 Kirou KA, Dall Era M, Aranow C, Anders HJ
• Race, Ethnicity, and Disparities in the Risk of End-Organ Lupus Manifestations Following a Systemic Lupus Erythematosus Diagnosis in a Multiethnic Cohort.
  Arthritis care & research 2022 Aguirre A, Izadi Z, Trupin L, Barbour KE, Greenlund KJ, Katz P, Lanata C, Criswell L, Dall'Era M, Yazdany J
• Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.
  Arthritis care & research 2022 Urowitz MB, Aranow C, Asukai Y, Bass DL, Bruce IN, Chauhan D, Dall'Era M, Furie R, Fox NL, Gilbride JA, Hammer A, Ginzler EM, Gonzalez-Rivera T, Levy RA, Merrill JT, Quasny H, Roth DA, Stohl W, van …
• The Impact of Telemedicine on Rheumatology Care.
  Frontiers in medicine 2022 Tang W, Inzerillo S, Weiner J, Khalili L, Barasch J, Gartshteyn Y, Dall'Era M, Aranow C, Mackay M, Askanase A
• Physical Inactivity and Incident Depression in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort.
  Arthritis care & research 2022 Patterson SL, Trupin L, Yazdany J, Dall'Era M, Lanata C, Dequattro K, Hartogensis W, Katz P
• High Disease Severity Among Asian Patients in a US Multiethnic Cohort of Individuals With Systemic Lupus Erythematosus.
  Arthritis care & research 2022 DeQuattro K, Trupin L, Murphy LB, Rush S, Criswell LA, Lanata CM, Dall'Era M, Katz P, Yazdany J
• Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus.
  Science (New York, N.Y.) 2022 Perez RK, Gordon MG, Subramaniam M, Kim MC, Hartoularos GC, Targ S, Sun Y, Ogorodnikov A, Bueno R, Lu A, Thompson M, Rappoport N, Dahl A, Lanata CM, Matloubian M, Maliskova L, Kwek SS, Li T, Slyper M,…
• A glimpse into the future of systemic lupus erythematosus.
  Therapeutic advances in musculoskeletal disease 2022 Aringer M, Alarcón-Riquelme ME, Clowse M, Pons-Estel GJ, Vital EM, Dall'Era M
• Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria.
  Lupus science & medicine 2022 van Vollenhoven R, Askanase AD, Bomback AS, Bruce IN, Carroll A, Dall'Era M, Daniels M, Levy RA, Schwarting A, Quasny HA, Urowitz MB, Zhao MH, Furie R
• Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials.
  The Lancet. Rheumatology 2022 Morand EF, Furie RA, Bruce IN, Vital EM, Dall'Era M, Maho E, Pineda L, Tummala R
• Increasing Ancestral Diversity in Systemic Lupus Erythematosus Clinical Studies.
  Arthritis care & research 2022 Williams JN, Dall'Era M, Lim SS, Feldman CH, Arntsen KA, Blazer AD, Goode T, Merrill JT, Sheikh S, Stevens AM, Lipsky PE, Costenbader KH
• Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries.
  Lupus science & medicine 2021 Izmirly PM, Ferucci ED, Somers EC, Wang L, Lim SS, Drenkard C, Dall'Era M, McCune WJ, Gordon C, Helmick C, Parton H
• Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network.
  Lupus science & medicine 2021 Deonaraine KK, Carlucci PM, Fava A, Li J, Wofsy D, James JA, Putterman C, Diamond B, Davidson A, Fine DM, Monroy-Trujillo J, Atta MG, Haag K, Rao DA, Apruzzese W, Belmont HM, Izmirly PM, Wu M, Connery…
• Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries.
  Arthritis & rheumatology (Hoboken, N.J.) 2021 Izmirly PM, Parton H, Wang L, McCune WJ, Lim SS, Drenkard C, Ferucci ED, Dall'Era M, Gordon C, Helmick CG, Somers EC
• Transcriptomic analysis of immune cells in a multi-ethnic cohort of systemic lupus erythematosus patients identifies ethnicity- and disease-specific expression signatures.
  Communications biology 2021 Andreoletti G, Lanata CM, Trupin L, Paranjpe I, Jain TS, Nititham J, Taylor KE, Combes AJ, Maliskova L, Ye CJ, Katz P, Dall'Era M, Yazdany J, Criswell LA, Sirota M
• Mortality Among Minority Populations with Systemic Lupus Erythematosus, Including Asian and Hispanic/Latino Persons - California, 2007-2017.
  MMWR. Morbidity and mortality weekly report 2021 Gianfrancesco MA, Dall'Era M, Murphy LB, Helmick CG, Li J, Rush S, Trupin L, Yazdany J
• Impact of Limited Health Literacy on Patient-Reported Outcomes in Systemic Lupus Erythematosus.
  Arthritis care & research 2021 Katz P, Dall'Era M, Trupin L, Rush S, Murphy LB, Lanata C, Criswell LA, Yazdany J
• Major Depression and Adverse Patient-Reported Outcomes in Systemic Lupus Erythematosus: Results From a Prospective Longitudinal Cohort.
  Arthritis care & research 2020 Dietz B, Katz P, Dall'Era M, Murphy LB, Lanata C, Trupin L, Criswell LA, Yazdany J
• Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.
  Arthritis & rheumatology (Hoboken, N.J.) 2020 Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, Barry WT, Gao W, Ryker K, Tosta P, Askanase AD, Boackle SA, Chatham WW, Kamen DL, Karp DR, Kirou KA, Sam Lim S, Marder B, McMahon…
• A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis.
  Rheumatology (Oxford, England) 2020 Aranow C, Cush J, Bolster MB, Striebich CC, Dall'era M, Mackay M, Olech E, Frech T, Box J, Keating R, Wasko MC, St Clair W, Kivitz A, Huang W, Ricketts P, Welch B, Callahan S, Spychala M, Boyle K, …
• Creatinine Fluctuation in Patients With Lupus Nephritis: Considerations for Clinical Trial Endpoints.
  Kidney international reports 2020 Almaani S, Bhatt U, Arriens C, Bonfa E, Dall'Era M, Houssiau F, Kalunian K, Mackay M, Sanchez-Guerrero J, Solomons N, Rovin BH
• Quality of Care for the Screening, Diagnosis, and Management of Lupus Nephritis Across Multiple Health Care Settings.
  Arthritis care & research 2020 Aggarwal I, Li J, Trupin L, Gaynon L, Katz PP, Lanata C, Criswell L, Murphy LB, Dall'Era M, Yazdany J
• Racial and Ethnic Differences in the Prevalence and Time to Onset of Manifestations of Systemic Lupus Erythematosus: The California Lupus Surveillance Project.
  Arthritis care & research 2020 Maningding E, Dall'Era M, Trupin L, Murphy LB, Yazdany J
• Relationships Between Adverse Childhood Experiences and Health Status in Systemic Lupus Erythematosus.
  Arthritis care & research 2020 DeQuattro K, Trupin L, Li J, Katz PP, Murphy LB, Yelin EH, Rush S, Lanata C, Criswell LA, Dall'Era M, Yazdany J
• Author Correction: A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus.
  Nature communications 2020 Lanata CM, Paranjpe I, Nititham J, Taylor KE, Gianfrancesco M, Paranjpe M, Andrews S, Chung SA, Rhead B, Barcellos LF, Trupin L, Katz P, Dall'Era M, Yazdany J, Sirota M, Criswell LA
• A Mobile Learning Module to Support Interprofessional Knowledge Construction in the Health Professions.
  American journal of pharmaceutical education 2020 Floren LC, Mandal J, Dall'Era M, Shin J, Irby DM, Cate OT, O'Brien BC
• Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patient-Reported Outcomes Measurement Information System Short Forms in Systemic Lupus Erythematosus.
  ACR open rheumatology 2019 Katz P, Pedro S, Alemao E, Yazdany J, Dall'Era M, Trupin L, Rush S, Michaud K
• Psychometric Evaluation of the National Institutes of Health Patient-Reported Outcomes Measurement Information System in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort.
  Arthritis care & research 2019 Katz P, Yazdany J, Trupin L, Rush S, Helmick CG, Murphy LB, Lanata C, Criswell LA, Dall'Era M
• Publisher Correction: The immune cell landscape in kidneys of patients with lupus nephritis.
  Nature immunology 2019 Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P,…
• A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus.
  Nature communications 2019 Lanata CM, Paranjpe I, Nititham J, Taylor KE, Gianfrancesco M, Paranjpe M, Andrews S, Chung SA, Rhead B, Barcellos LF, Trupin L, Katz P, Dall'Era M, Yazdany J, Sirota M, Criswell LA
• The immune cell landscape in kidneys of patients with lupus nephritis.
  Nature immunology 2019 Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P,…
• Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial.
  PLoS medicine 2019 Singh JA, Fraenkel L, Green C, Alarcón GS, Barton JL, Saag KG, Hanrahan LM, Raymond SC, Kimberly RP, Leong AL, Reyes E, Street RL, Suarez-Almazor ME, Eakin GS, Marrow L, Morgan CJ, Caro B, Sloan JA, …
• Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis.
  Lupus science & medicine 2019 Gomez Mendez LM, Cascino MD, Katsumoto TR, Brakeman P, Brunetta P, Jayne D, Dall'Era M, Rovin B, Garg J
• Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes.
  Arthritis & rheumatology (Hoboken, N.J.) 2019 Mackay M, Dall'Era M, Fishbein J, Kalunian K, Lesser M, Sanchez-Guerrero J, Levy DM, Silverman E, Petri M, Arriens C, Lewis EJ, Korbet SM, Conti F, Tesar V, Hruskova Z, Borba EF, Bonfa E, Chan TM, …
• Adoptive Treg Cell Therapy in a Patient With Systemic Lupus Erythematosus.
  Arthritis & rheumatology (Hoboken, N.J.) 2019 Dall'Era M, Pauli ML, Remedios K, Taravati K, Sandova PM, Putnam AL, Lares A, Haemel A, Tang Q, Hellerstein M, Fitch M, McNamara J, Welch B, Bluestone JA, Wofsy D, Rosenblum MD, Autoimmunity Centers …
• Current challenges in the development of new treatments for lupus.
  Annals of the rheumatic diseases 2019 Dall'Era M, Bruce IN, Gordon C, Manzi S, McCaffrey J, Lipsky PE
• Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study.
  Annals of the rheumatic diseases 2018 Sciascia S, Yazdany J, Dall'Era M, Fenoglio R, Radin M, Aggarwal I, Cuadrado MJ, Schreiber K, Barreca A, Papotti M, Roccatello D
• Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis.
  Clinical journal of the American Society of Nephrology : CJASN 2018 Gomez Mendez LM, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall'Era M, Looney RJ, Rovin B, Dragone L, Brunetta P
• Lupus community panel proposals for optimising clinical trials: 2018.
  Lupus science & medicine 2018 Merrill JT, Manzi S, Aranow C, Askanase A, Bruce I, Chakravarty E, Chong B, Costenbader K, Dall'Era M, Ginzler E, Hanrahan L, Kalunian K, Merola J, Raymond S, Rovin B, Saxena A, Werth VP
• The Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, California: The California Lupus Surveillance Project.
  Arthritis & rheumatology (Hoboken, N.J.) 2017 Dall'Era M, Cisternas MG, Snipes K, Herrinton LJ, Gordon C, Helmick CG
• Treatment of lupus nephritis: current paradigms and emerging strategies.
  Current opinion in rheumatology 2017 Dall'Era M
• Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence.
  Rheumatology international 2017 Sciascia S, Radin M, Yazdany J, Tektonidou M, Cecchi I, Roccatello D, Dall'Era M
• Mapping Perceptions of Lupus Medication Decision-Making Facilitators: The Importance of Patient Context.
  Arthritis care & research 2016 Qu H, Shewchuk RM, Alarcón G, Fraenkel L, Leong A, Dall'Era M, Yazdany J, Singh JA
• Blood-Borne RNA Correlates with Disease Activity and IFN-Stimulated Gene Expression in Systemic Lupus Erythematosus.
  Journal of immunology (Baltimore, Md. : 1950) 2016 Doedens JR, Jones WD, Hill K, Mason MJ, Gersuk VH, Mease PJ, Dall'Era M, Aranow C, Martin RW, Cohen SB, Fleischmann RM, Kivitz AJ, Burge DJ, Chaussabel D, Elkon KB, Posada JA
• A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial.
  Lupus science & medicine 2015 Tamirou F, Lauwerys BR, Dall'Era M, Mackay M, Rovin B, Cervera R, Houssiau FA, MAINTAIN Nephritis Trial Investigators
• Barriers to Medication Decision Making in Women with Lupus Nephritis: A Formative Study using Nominal Group Technique.
  The Journal of rheumatology 2015 Singh JA, Qu H, Yazdany J, Chatham W, Dall'era M, Shewchuk RM
• Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus.
  Arthritis & rheumatology (Hoboken, N.J.) 2015 Aranow C, Kamen DL, Dall'Era M, Massarotti EM, Mackay MC, Koumpouras F, Coca A, Chatham WW, Clowse ME, Criscione-Schreiber LG, Callahan S, Goldmuntz EA, Keyes-Elstein L, Oswald M, Gregersen PK, …
• Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome.
  Lupus science & medicine 2015 Dall'Era M, Levesque V, Solomons N, Truman M, Wofsy D
• Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort.
  Arthritis & rheumatology (Hoboken, N.J.) 2015 Dall'Era M, Cisternas MG, Smilek DE, Straub L, Houssiau FA, Cervera R, Rovin BH, Mackay M
• A young woman with systemic lupus erythematosus and extensive mesenteric vasculitis involving small and medium vessels.
  Arthritis care & research 2012 Ashouri JF, Davis JL, Farkas A, Durack JC, Ramachandran R, Dall'Era M
• Mycophenolate mofetil in the treatment of systemic lupus erythematosus.
  Current opinion in rheumatology 2011 Dall'Era M
• Brief index of lupus damage: a patient-reported measure of damage in systemic lupus erythematosus.
  Arthritis care & research 2011 Yazdany J, Trupin L, Gansky SA, Dall'era M, Yelin EH, Criswell LA, Katz PP
• Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies.
  Current rheumatology reports 2011 Dall'era M, Chakravarty EF
• Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide.
  Arthritis care & research 2010 Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D
• B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.
  Arthritis research & therapy 2010 Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, Hamacher NB, Lantry MM, Maurer M, Krejsa CM, Ellsworth JL, Pederson S, Elkon KB, Wener MH, Dall'Era M, Gross JA
• Connective tissue diseases: Belimumab for systemic lupus erythematosus: breaking through?
  Nature reviews. Rheumatology 2010 Dall'Era M, Wofsy D
• Biologic therapy for systemic lupus erythematosus.
  Discovery medicine 2010 Dall'Era M, Wofsy D
• Systemic lupus erythematosus clinical trials-an interim analysis.
  Nature reviews. Rheumatology 2009 Dall'Era M, Wofsy D
• Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.
  Arthritis and rheumatism 2007 Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D
• Six refractory lupus patients treated with rituximab: a case series.
  Arthritis and rheumatism 2007 Gillis JZ, Dall'era M, Gross A, Yazdany J, Davis J
• Clinical trial design in systemic lupus erythematosus.
  Current opinion in rheumatology 2006 Dall'Era M, Wofsy D
• Systemic lupus erythematosus. How to manage, when to refer.
  Postgraduate medicine 2003 Dall'Era M, Davis JC